Results 211 to 220 of about 99,091 (316)

An Exploratory Investigation of Representations of Herpes Zoster and Adjuvanted Recombinant Herpes Zoster Vaccination in a Sample of Fragile Adults in Italy. [PDF]

Pathogens
De Caro F, Pecoraro N, Capunzo M, Caruccio S, Caggiano F, Cersosimo G, Costantino M, Longanella W, Malatesta F, Tomeo M, Savarese G, Sinopoli P, Vozzella EA, Moccia G.   +13 more
europepmc   +1 more source

A point mutation in the putative ATP binding site of the pseudorabies virus US3 protein kinase prevents Bad phosphorylation and cell survival following apoptosis induction [PDF]

, 2007
Deruelle, Matthias, Favoreel, Herman, Geenen, Kristin, Nauwynck, Hans   +3 more
core   +2 more sources

Clinical characteristics and treatment of varicella zoster virus central nervous system infection in an Australian tertiary hospital

Internal Medicine Journal, Volume 55, Issue 7, Page 1152-1160, July 2025.
Abstract Background and Aim Varicella zoster virus (VZV) is a neurotropic herpesvirus. With improved access to molecular diagnostics, there is increasing recognition of VZV with central nervous system involvement. This study aimed to describe the demographic, clinical and treatment characteristics of patients admitted to an Australian tertiary hospital
Connie Lam, Eve Chen, Arthur Thevathasan, Terry Yan, Michael Moso, Joe Sasadeusz, Stephen Muhi   +6 more
wiley   +1 more source

Brief Report: Cytosine Arabinoside Therapy for Disseminated Herpes Zoster in a Patient with IgG Pyroglobulinemia [PDF]

, 1969
Eugene M. McKelvey, Hau C. Kwaan
openalex   +1 more source

Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 7, Page 1336-1351, July 2025.
In this analysis of the long‐term safety and efficacy of deucravacitinib in patients with moderate to severe plaque psoriasis treated through 4 years, no new safety signals were observed compared with the first year. Patients continuously treated with deucravacitinib from Day 1 maintained clinical and patient‐reported outcome response rates.
April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Akimichi Morita, Carle Paul, Kim A. Papp, Matthew J. Colombo, Julie Scotto, John Vaile, Joe Zhuo, Eleni Vritzali, Victoria Berger, Georgene Schroeder, Subhashis Banerjee, Diamant Thaçi, Bruce Strober   +16 more
wiley   +1 more source

Herpes zoster prevalence following epidural steroid injections: a retrospective review. [PDF]

Interv Pain Med
Furtado-Pessoa-de-Mendonca L, Encalada S, Hallo-Carrasco A, Mosquera-Moscoso J, Cascio MA, Pagan-Rosado R, Osborne MD, Eldrige JS, Hunt CL.   +8 more
europepmc   +1 more source

Herpes Zoster and Multiple Sclerosis [PDF]

, 1969
J. A. R. Lenman, T. J. Peters
openalex   +1 more source

Herpes Zoster [PDF]

BMJ, 1956
openaire   +2 more sources

Paralysis in herpes zoster. [PDF]

, 1970
Jenni Anderson
openalex   +3 more sources

A natural experiment on the effect of herpes zoster vaccination on dementia. [PDF]

Nature
Eyting M, Xie M, Michalik F, Heß S, Chung S, Geldsetzer P.   +5 more
europepmc   +1 more source